

Glaucoma Research Society Meeting

Seoul, Korea, 31 August – 3 September 2016

SCIENTIFIC PROGRAMME

THURSDAY 1 SEPTEMBER

Session 1: Predicting risk in glaucoma: biomarkers, bad genes and beyond

Chairs: J. Wiggs, D. Mackey

- 08.00 T. Aung G-WAS. What IS the next big thing?
- 08.20 F. Grus (candidate) Fab biomarkers: future approaches for diagnosing glaucoma
- 08.40 J. Jeoung Mitochondrial DNA as a risk predictor in glaucoma
- 09.00 D. Mackey How can we fulfil the promise of modern genetics?
- 09.20 S. Orgul Bad blood, reactive vessels and blood pressure
- 09.40 DISCUSSION
- 10.00 BREAK

Session 2: Comparing glaucoma to other neurodegenerative conditions

Chairs: F. Topouzis, S. Gandolfi

- 10.30 A. Clark Hallmarks of neurodegenerative diseases - concepts and pathogenesis
- 10.50 N. Gupta Vascular factors in neurodegenerative diseases and glaucoma
- 11.10 C. Burgoyne Neural tissue under pressure: ONH – IOP vs CNS – CSF
- 11.30 N. Pfeiffer Current treatment approaches in AD, PD etc - what can we learn?
- 11.50 P. Foster Can RNFL thickness predict cognitive decline?
- 12.10 A. Coleman Epidemiology of glaucoma and other NDD: comorbidities and risk
- 12:30 LUNCH

Session 3: The ageing optic nerve

Chairs: J. Crowston, G. Cioffi, C. Tham

- | | | |
|-------|----------------------|--|
| 13.30 | H. Levkovitch-Verbin | Ageing and endogenous neuroprotection |
| 13.50 | L. Pasquale | Estrogen deficiency accelerates aging of the optic nerve |
| 14.10 | R. Ethier | Biomechanics and ageing |
| 14.30 | T. Yamamoto | Ageing and trabeculectomy |
| 14.50 | A. Robin | Managing the ageing epidemic in glaucoma |
| 15.10 | BREAK | |

Session 4: RGC degeneration and regeneration: where are we now?

Chairs: K. Martin, A. Clark, N. Gupta

- | | | |
|-------|------------|---|
| 15.40 | H. Quigley | What is really happening at the optic nerve head? |
| 16.00 | K. Martin | Stimulating RGC regeneration |
| 16.20 | R. Ritch | Non-IOP dependent mechanisms in glaucoma |
| 16.40 | K. Park | Neuroprotection with nanomedicine |

FRIDAY 2 SEPTEMBER

Session 5: From phenotyping to personalised medicine in glaucoma

Chairs: H. Levkovitch-Verbin, R. Thomas, J. Jonas

- | | | |
|-------|--------------------|--|
| 08.00 | F. Topouzis | Risk assessment of the glaucoma patient |
| 08.20 | A. Khawaja (guest) | The association between risk factors and phenotype |
| 08.40 | L. Vijaya | Tailoring treatment to the patient |
| 09.00 | I. Goldberg | The challenges ahead |

Session 6: Goldmann Lecture

- | | | |
|-------|----------------------------|--|
| 09.20 | Introduction – Franz Grehn | |
| 09.25 | A. Heijl | |
| 10.00 | BREAK | |

Session 7: What is needed to move to remote management of glaucoma?

Chairs: D. Friedman, M. He

- | | | |
|-------|---------------------|--|
| 10.30 | D. Friedman | Basics of telemedicine for glaucoma |
| 10.50 | K. Mansouri (guest) | Home tonometry |
| 11.10 | R. Sihota | Telemedicine in the developing world |
| 11.30 | G. Gazzard (guest) | Funding of telemedicine (how would it really work) |

11:50 BUSINESS MEETING

12:45 LUNCH

SATURDAY 3 SEPTEMBER

Session 8: Outcome measures for clinical trials

Chairs: D. Garway-Heath, L. Levin (guest), L. Schmetterer

- | | | |
|-------|-----------------------|---|
| 08.30 | P. Ramulu (candidate) | QoL and patient-related outcomes |
| 08.50 | J. Caprioli | How much change is clinically relevant? |
| 09.10 | B. Chauhan | Rate of VF change as an outcome |
| 09.30 | D. Garway-Heath | Structure outcomes |
| 09.50 | C. Leung | DISCUSSION and CONCLUSIONS |
| 10.10 | BREAK | |

Session 9: Candidate GRS Member Presentations

Chairs: F. Grehn, A. Heijl, C. Liu

- | | | |
|-------|------------------|---|
| 10.40 | J. Wiggs | POAG genetics: Insights into a complex disease |
| 11.00 | R. Allingham | Eyes of Africa: Human diversity, genes, and glaucoma |
| 11.20 | T. Nakazawa | New approaches to Neuroprotection |
| 11.40 | K. Singh | Disease surveillance and glaucoma risk |
| 12.00 | A. Azuara-Blanco | Initial treatment of angle-closure glaucoma: should clear lens extraction replace laser peripheral iridotomy? |
| 12.20 | LUNCH | |

Session 10: How will we be diagnosing and treating glaucoma in 2030?

Chairs: H. Quigley, N. Wang, K. Park

- 13.20 P. Khaw "10:10:10"
- 13.40 J. Crowston Measuring neurorecovery in RGCs
- 14.00 J. Brandt Future technologies: how will they change what we do?
- 14.20 F. Medeiros The virtual future
- 15.40 DISCUSSION
- 15.00 BREAK

Session 11: How do we know we are doing any good?

Chairs: A. Coleman, R. Wormald

- 15.30 A. Tuulonen Impact of glaucoma care – the societal perspective
- 15.50 P. Lee Impact of glaucoma care – the patient perspective
- 16.10 G. Cioffi Effectiveness of care
- 16.30 H. Jampel Patient experience under care
- 17.00 MEETING ADJOURNS